• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

METHYLPHENIDATE Drug Record

  • Summary
  • Interactions
  • Claims
  • METHYLPHENIDATE chembl:CHEMBL796 Approved

    Alternate Names:

    METHYLIN
    CONCERTA
    COTEMPLA XR-ODT
    DAYTRANA
    METHYLPHENIDATE

    Drug Info:

    Drug Class central nervous system stimulants
    Year of Approval approved before 1982
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of ADHD
    (3 More Sources)

    Publications:

    Pagerols M et al., 2017, Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder., Pharmacogenomics J
    Pagerols M et al., 2018, Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder., Sci Rep
    Myer NM et al., 2018, Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD., Mol Psychiatry
    Park S et al., 2014, Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea., J Psychopharmacol
    Yatsuga C et al., 2014, No association between catechol-O-methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children., Brain Dev
    Contini V et al., 2012, No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD., J Clin Psychopharmacol
    Green T et al., 2011, The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome., J Child Adolesc Psychopharmacol
    Salatino-Oliveira A et al., 2011, Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder., Biol Psychiatry
    Cheon KA et al., 2008, Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder., Int Clin Psychopharmacol
    Kereszturi E et al., 2008, Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children., Am J Med Genet B Neuropsychiatr Genet
    Volkow et al., 1999, Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain., Synapse
    Volkow et al., 1999, Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain., Life Sci.
    Wayment et al., 1999, Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists?, J. Neurochem.
    Viggiano et al., 2004, Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling., Neural Plast.
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Dresel et al., 1999, In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates., Eur J Nucl Med
    Tilley et al., 2008, The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter., J. Pharmacol. Exp. Ther.
    Izenwasser et al., 1999, Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine., Eur. J. Pharmacol.
    Stein et al., 2005, Dopamine transporter genotype and methylphenidate dose response in children with ADHD., Neuropsychopharmacology
    Cheon et al., 2005, The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate., Eur Neuropsychopharmacol
    Trinh et al., 2003, Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice., Neuroscience
    Markowitz JS et al., 2006, A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study., J Child Adolesc Psychopharmacol
    Berridge CW et al., 2006, Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function., Biol Psychiatry
    Angyal N et al., 2018, Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients., Prog Neuropsychopharmacol Biol Psychiatry
    Kim BN et al., 2013, Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder., J Clin Psychopharmacol
    Hong SB et al., 2012, Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?, J Child Adolesc Psychopharmacol
    Gray et al., 2007, Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress., J. Neurosci.
    Chuhan et al., 2006, Impairment of single-trial memory formation by oral methylphenidate in the rat., Neurobiol Learn Mem
    Sandoval et al., 2001, Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model., J. Neurosci.
    Yang et al., 2004, Association of norepinephrine transporter gene with methylphenidate response., J Am Acad Child Adolesc Psychiatry
    Williard et al., 2007, Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity., Behav Pharmacol
    Levy F et al., 2013, Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attention-deficit/hyperactivity disorder., J Child Adolesc Psychopharmacol
    Kim SW et al., 2013, ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD., J Clin Psychopharmacol
    Stehouwer et al., 2006, Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography., J. Med. Chem.
    Elangovan et al., 1996, Neurohormonal and behavioral response to methylphenidate in cocaine abstinence., Psychiatry Res
    Weizman et al., 1987, Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity., Life Sci.
    DeVane et al., 2000, Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers., J Clin Psychopharmacol
    Bruxel EM et al., 2015, LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study., Genes Brain Behav
    Song J et al., 2014, Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder., Clin Neuropharmacol
    Labbe A et al., 2012, Refining psychiatric phenotypes for response to treatment: contribution of LPHN3 in ADHD., Am J Med Genet B Neuropsychiatr Genet
    Choudhry Z et al., 2012, LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy., J Child Psychol Psychiatry
    Arcos-Burgos M et al., 2010, A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication., Mol Psychiatry
    Kim JI et al., 2017, Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder., J Psychopharmacol
    Nemoda Z et al., 2009, Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD., Neuropharmacology
    McCracken JT et al., 2014, Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders., Pharmacogenomics J
  • METHYLPHENIDATE   ADGRL3

    Interaction Score: 4.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29230023 25989180 25229170 22851411 22486528 20157310


    Sources:
    PharmGKB

  • METHYLPHENIDATE   OPCML

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ZNF134

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   NFIB

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ESYT2

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   PURA

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ZNF565

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   CHURC1

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ZDHHC7

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ARHGEF28

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ARHGAP12

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ETFDH

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   SENP3

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ZNF211

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   PEBP4

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   GET1

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   FARP2

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   FXR2

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   TRIB3

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   CORO7

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   CMTM8

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   PIGM

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   CDH23

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ELP5

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   PDIA2

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   RRP7A

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   SPSB2

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ALDH1L1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHYLPHENIDATE   SLC6A2

    Interaction Score: 0.56

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name methylphenidate HCl,Ritalin LA
    Trial Name methylphenidate HCl,Metadate CD, Equasym
    Novel drug target Established target

    PMIDs:
    29374517 29230023 23609393 23083021 17611273 9537821 16246598 11160413 15322419 17218796 18698001 16806100 17201613


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • METHYLPHENIDATE   GGH

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   SLC6A3

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine transporter inhibitor
    Direct Interaction yes
    Trial Name Daytrana

    PMIDs:
    10025684 10403500 10037500 15303308 9537821 11752352 10199939 18698001 10414438 15827573 15572278 12699766 17201613 16806100


    Sources:
    TdgClinicalTrial ChemblInteractions NCI TEND TTD

  • METHYLPHENIDATE   COMT

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29230023 24763183 24035255 23131881 22149470 21550019 18703939 18214865


    Sources:
    PharmGKB

  • METHYLPHENIDATE   CES1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19733552


    Sources:
    PharmGKB

  • METHYLPHENIDATE   TH

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26810137


    Sources:
    PharmGKB

  • METHYLPHENIDATE   SLC6A4

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name methylphenidate HCl,Concerta
    Novel drug target Established target
    Trial Name methylphenidate HCl,Metadate CD, Equasym

    PMIDs:
    10199939 17154506 10414438


    Sources:
    TdgClinicalTrial TEND

  • METHYLPHENIDATE   ARSA

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   PRL

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9122287 3035307


    Sources:
    NCI

  • METHYLPHENIDATE   GRIN2B

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27624150


    Sources:
    PharmGKB

  • METHYLPHENIDATE   DRD3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23856854


    Sources:
    PharmGKB

  • METHYLPHENIDATE   NAT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Norepinephrine transporter inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • METHYLPHENIDATE   DRD1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23952191


    Sources:
    PharmGKB

  • METHYLPHENIDATE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26810137


    Sources:
    PharmGKB

  • METHYLPHENIDATE   HTT

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29382897


    Sources:
    PharmGKB

  • METHYLPHENIDATE   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23771192


    Sources:
    PharmGKB

  • METHYLPHENIDATE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10831022


    Sources:
    NCI

  • TEND: METHYLPHENIDATE

    • Version: 01-August-2011

    Alternate Names:
    METHYLPHENIDATE Primary Drug Name

    Drug Info:
    Year of Approval approved before 1982
    Drug Class central nervous system stimulants

    Publications:

  • TdgClinicalTrial: METHYLPHENIDATE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of ADHD
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: METHYLPHENIDATE

    • Version: 14-September-2017

    Alternate Names:
    C646 NCI drug code

    Drug Info:

    Publications:
    DeVane et al., 2000, Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers., J Clin Psychopharmacol
    Elangovan et al., 1996, Neurohormonal and behavioral response to methylphenidate in cocaine abstinence., Psychiatry Res
    Weizman et al., 1987, Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity., Life Sci.

  • PharmGKB: methylphenidate

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Pagerols M et al., 2017, Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder., Pharmacogenomics J
    Pagerols M et al., 2018, Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder., Sci Rep
    Song J et al., 2014, Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder., Clin Neuropharmacol

  • TTD: Methylphenidate

    • Version: 2020.06.01

    Alternate Names:
    D02PPN TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL796

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL796

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21